Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia

Karen L. Mackenzie, Sonia Franco, Afzal J. Naiyer, Chad May, Michel Sadelain, Shahin Rafii, Malcolm A S Moore

Research output: Contribution to journalArticle

Abstract

We conducted a nonrandomized prospective phase II study of thalidomide in anemic patients with myelofibrosis with myeloid metaplasia (MMM), with or without preceding polycythemia vera or essential thrombocythemia, with a primary aim to improve anemia. Thalidomide was given in escalating doses with a target dose of 800 mg daily, but the median dose of thalidomide that was actually tolerated was 400 mg daily. Fifteen patients were entered into the study and 14 were evaluable for response. Five of 14 (36%) patients discontinued thalidomide before 3 mo because of side effects, and none of these five patients had a response at the time when thalidomide was stopped. When evaluated after 3 mo of therapy, none of the remaining nine patients exhibited a discernible clinical response. Three patients showed progressive disease defined as > 50% increase in the need for red cell transfusions. Treatment was poorly tolerated, with all patients reporting side effects of thalidomide, the most prominent being fatigue documented in 80% of patients. Two patients died while on study, one from acute myelogenous leukemia and one from pneumonia. We conclude that thalidomide given in doses employed in the treatment of multiple myeloma gives no clinically relevant hematological effects in advanced MMM and is hampered by a very high incidence of side effects.

Original languageEnglish (US)
Pages (from-to)79-86
Number of pages8
JournalMedical Oncology
Volume19
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Primary Myelofibrosis
Thalidomide
Essential Thrombocythemia
Polycythemia Vera
Multiple Myeloma
Acute Myeloid Leukemia
Fatigue
Anemia
Pneumonia
Therapeutics
Incidence

Keywords

  • Adverse events
  • Anemia
  • Blood transfusions
  • Myeloproliferative disorders
  • Myeofibrosis
  • Spleen
  • Thalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Mackenzie, K. L., Franco, S., Naiyer, A. J., May, C., Sadelain, M., Rafii, S., & Moore, M. A. S. (2002). Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Medical Oncology, 19(2), 79-86. https://doi.org/10.1385/MO:19:2:79

Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. / Mackenzie, Karen L.; Franco, Sonia; Naiyer, Afzal J.; May, Chad; Sadelain, Michel; Rafii, Shahin; Moore, Malcolm A S.

In: Medical Oncology, Vol. 19, No. 2, 2002, p. 79-86.

Research output: Contribution to journalArticle

Mackenzie, KL, Franco, S, Naiyer, AJ, May, C, Sadelain, M, Rafii, S & Moore, MAS 2002, 'Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia', Medical Oncology, vol. 19, no. 2, pp. 79-86. https://doi.org/10.1385/MO:19:2:79
Mackenzie, Karen L. ; Franco, Sonia ; Naiyer, Afzal J. ; May, Chad ; Sadelain, Michel ; Rafii, Shahin ; Moore, Malcolm A S. / Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. In: Medical Oncology. 2002 ; Vol. 19, No. 2. pp. 79-86.
@article{291627d8091f43088d3663ed1affb652,
title = "Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia",
abstract = "We conducted a nonrandomized prospective phase II study of thalidomide in anemic patients with myelofibrosis with myeloid metaplasia (MMM), with or without preceding polycythemia vera or essential thrombocythemia, with a primary aim to improve anemia. Thalidomide was given in escalating doses with a target dose of 800 mg daily, but the median dose of thalidomide that was actually tolerated was 400 mg daily. Fifteen patients were entered into the study and 14 were evaluable for response. Five of 14 (36{\%}) patients discontinued thalidomide before 3 mo because of side effects, and none of these five patients had a response at the time when thalidomide was stopped. When evaluated after 3 mo of therapy, none of the remaining nine patients exhibited a discernible clinical response. Three patients showed progressive disease defined as > 50{\%} increase in the need for red cell transfusions. Treatment was poorly tolerated, with all patients reporting side effects of thalidomide, the most prominent being fatigue documented in 80{\%} of patients. Two patients died while on study, one from acute myelogenous leukemia and one from pneumonia. We conclude that thalidomide given in doses employed in the treatment of multiple myeloma gives no clinically relevant hematological effects in advanced MMM and is hampered by a very high incidence of side effects.",
keywords = "Adverse events, Anemia, Blood transfusions, Myeloproliferative disorders, Myeofibrosis, Spleen, Thalidomide",
author = "Mackenzie, {Karen L.} and Sonia Franco and Naiyer, {Afzal J.} and Chad May and Michel Sadelain and Shahin Rafii and Moore, {Malcolm A S}",
year = "2002",
doi = "10.1385/MO:19:2:79",
language = "English (US)",
volume = "19",
pages = "79--86",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia

AU - Mackenzie, Karen L.

AU - Franco, Sonia

AU - Naiyer, Afzal J.

AU - May, Chad

AU - Sadelain, Michel

AU - Rafii, Shahin

AU - Moore, Malcolm A S

PY - 2002

Y1 - 2002

N2 - We conducted a nonrandomized prospective phase II study of thalidomide in anemic patients with myelofibrosis with myeloid metaplasia (MMM), with or without preceding polycythemia vera or essential thrombocythemia, with a primary aim to improve anemia. Thalidomide was given in escalating doses with a target dose of 800 mg daily, but the median dose of thalidomide that was actually tolerated was 400 mg daily. Fifteen patients were entered into the study and 14 were evaluable for response. Five of 14 (36%) patients discontinued thalidomide before 3 mo because of side effects, and none of these five patients had a response at the time when thalidomide was stopped. When evaluated after 3 mo of therapy, none of the remaining nine patients exhibited a discernible clinical response. Three patients showed progressive disease defined as > 50% increase in the need for red cell transfusions. Treatment was poorly tolerated, with all patients reporting side effects of thalidomide, the most prominent being fatigue documented in 80% of patients. Two patients died while on study, one from acute myelogenous leukemia and one from pneumonia. We conclude that thalidomide given in doses employed in the treatment of multiple myeloma gives no clinically relevant hematological effects in advanced MMM and is hampered by a very high incidence of side effects.

AB - We conducted a nonrandomized prospective phase II study of thalidomide in anemic patients with myelofibrosis with myeloid metaplasia (MMM), with or without preceding polycythemia vera or essential thrombocythemia, with a primary aim to improve anemia. Thalidomide was given in escalating doses with a target dose of 800 mg daily, but the median dose of thalidomide that was actually tolerated was 400 mg daily. Fifteen patients were entered into the study and 14 were evaluable for response. Five of 14 (36%) patients discontinued thalidomide before 3 mo because of side effects, and none of these five patients had a response at the time when thalidomide was stopped. When evaluated after 3 mo of therapy, none of the remaining nine patients exhibited a discernible clinical response. Three patients showed progressive disease defined as > 50% increase in the need for red cell transfusions. Treatment was poorly tolerated, with all patients reporting side effects of thalidomide, the most prominent being fatigue documented in 80% of patients. Two patients died while on study, one from acute myelogenous leukemia and one from pneumonia. We conclude that thalidomide given in doses employed in the treatment of multiple myeloma gives no clinically relevant hematological effects in advanced MMM and is hampered by a very high incidence of side effects.

KW - Adverse events

KW - Anemia

KW - Blood transfusions

KW - Myeloproliferative disorders

KW - Myeofibrosis

KW - Spleen

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=0036017505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036017505&partnerID=8YFLogxK

U2 - 10.1385/MO:19:2:79

DO - 10.1385/MO:19:2:79

M3 - Article

C2 - 12180484

AN - SCOPUS:0036017505

VL - 19

SP - 79

EP - 86

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 2

ER -